Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Austin Miller

Asst Professor of Oncology, Biostatistics and Bioinformatics

Roswell Park Comprehensive Cancer Center

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

.

ORCID

.

LinkedIn

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI

Contact this professor

LinkedIn

Google Scholar

Research Interests

Obstetrics And Gynecology

20%

Pharmacotherapy

30%

Gynecologic Oncology

40%

Ovarian Cancer

40%

Oncology

40%

Targeted Therapy

30%

Cancer Biology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles13

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

Year:

2025

Improving the Estimation of Prediction Increment Measures in Logistic and Survival Analysis

Year:

2025

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Year:

2024

Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors

Year:

2023

Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.

Year:

2023

Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

Year:

2023

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Year:

2022

Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.

Year:

2022

Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)

Year:

2022

Survival with Cemiplimab in Recurrent Cervical Cancer.

Year:

2022

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.

Year:

2022

Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

Year:

2021

A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.

Year:

2021

Collaborators6

Samuel Mok

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Christina Washington

University of Oklahoma Health Sciences Center

UNITED STATES

C Simon Herrington

Professor

University of Edinburgh

UNITED KINGDOM

Emese Zsiros

Associate Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES

Craig Freyer

Hospital of the University of Pennsylvania

UNITED STATES

Kevin Eng

Research Assistant Professor

State University of New York at Buffalo

UNITED STATES

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI